Moderna reaffirms 2023 COVID vaccine gross sales forecast of $5bn

Moderna Inc reaffirmed its annual gross sales forecast of $5 billion for its COVID-19 vaccines, which was beneath market expectations as the corporate anticipated decrease demand within the fourth 12 months of the pandemic.

Gross sales of the COVID vaccine, Moderna’s sole industrial product, have been broadly anticipated to fall sharply this 12 months from $18.4 billion in 2022.

Moderna’s forecast was decrease than Refinitiv estimates of $6.98 billion.

The corporate additionally reiterated its plans to file for regulatory approval its respiratory syncytial virus vaccine within the first half of 2023 because it seems to construct its product portfolio past COVID vaccines.